Skip to content
Governance Register

← US public companies

Optimer Pharmaceuticals INC

SEC CIK 1142576 · OPTR · last insider filing 2013-10-28

Directors (from insider filings)

NameCapacity as filedFilings
Auerbach Mark Director filed 2007 - 2013
Mckinnell Henry A Director · CEO and Chairman of the Board filed 2011 - 2013
Chang Joseph Y Director filed 2007 - 2013
Grebow Peter E Director filed 2009 - 2013
Zerbe Robert L MD Director filed 2009 - 2013
Chang Michael N Director · President, CEO filed 2007 - 2013
Newman Stephen L Director filed 2012 - 2013
Altig Anthony E Director filed 2007 - 2013
Lichtinger Pedro Director · President and CEO filed 2010 - 2013
Frapaise Francois-Xavier Director · SVP, Chief Scientific Officer filed 2009 - 2010
Schreiber Alain Director filed 2007 - 2010
Muenchbach Martin Director filed 2007 - 2007
Lee Howard Director filed 2007 - 2007
Chow Joseph Director filed 2007 - 2007

Officers (from insider filings)

NameTitle as filedFilings
Amper Linda E SVP, Human Resources filed 2011 - 2013
Gorbach MD Sherwood Senior VP, Chief Medical Offic filed 2007 - 2013
Webster Stephen W Chief Financial Officer filed 2012 - 2013
Schaum Meredith Gen.Counsel and Chief Comp Off filed 2013 - 2013
Sirota Eric Chief Operating Officer filed 2013 - 2013
Hartman Kurt M General Counsel, SVP filed 2010 - 2012
Papaz Gregory E. SVP, Commercial Operations filed 2010 - 2012
Prunty John D CFO, and VP, Finance filed 2007 - 2012
Shue Youe Kong VP, clinical Development filed 2007 - 2012
Che Tessie M Sr. VP, Corporate Affairs filed 2007 - 2012
Poulos Kevin P VP, Marketing and Sales filed 2007 - 2010

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.